Esketamine (Spravato) – Generic Status & Price Snapshot (2024‑2026)
| Item | Details |
|------|---------|
| Generic approval (FDA, US) | None. The FDA has not approved any esketamine generic. The brand‑name product (Spravato) remains the only commercially available formulation in the United States. |
| Generic approval (other major markets) | • European Union: no approved generic.
• Canada: no approved generic.
• Australia: no approved generic.
• India, Brazil, and several Asian countries have unregistered or “import‑only” versions that are not FDA‑approved and are typically used under special‑access or compassionate‑use programs. |
| When might a generic hit the market? | – Patent on Spravato expires in 2029 in the U.S.
– Even after patent expiration, a generic would require the sponsor to submit a “Abbreviated New Drug Application (ANDA)” that includes a waiver of the “Abbreviated” requirement for a nasal spray; this is a complex, costly process.
– Industry analysts project a generic launch window of 2029‑2031 if a sponsor is prepared to invest the necessary resources. |
| Current brand‑price (US) | • Typical cost per vial (56 mg): $650–$800 (price fluctuates by pharmacy, region, and insurance).
• Each vial contains a single dose; a typical treatment schedule is 2–4 mg/kg, which for a 70 kg adult is about 140 mg—meaning 2–3 vials per administration.
• The nasal‑spray device (which can be reused for up to 3 months) costs an additional $15–$30. |
| Cost per treatment session | • Assuming 140 mg (2 vials) = ~$1,300–$1,600
• With device = ~$1,320–$1,630.
• If you’re on a 2‑week cycle, that’s roughly $2,600–$3,200 every 4 weeks, before insurance. |
| Insurance / CMS coverage | • Spravato is Medicare Part B‑covered as a specialty drug.
• Many commercial insurers (e.g., Aetna, Blue Cross Blue Shield) cover the drug with prior authorization.
• The out‑of‑pocket cost after insurance typically ranges from $0–$100 per dose, depending on the plan’s formulary tier and patient deductible. |
| Alternative cost‑saving strategies | 1. Patient Assistance Programs (PAP) – The manufacturer offers a free or discounted program for patients who qualify based on income and insurance status.
2. Copay cards – Available for a limited number of doses per year.
3. Clinical trial enrollment – Some studies are still recruiting patients for esketamine, which can provide free medication. |
| What to do if you’re looking for a generic | 1. Ask your prescriber – They can verify whether any generic has entered the market or if a “substitute” (e.g., a different brand of ketamine nasal spray) is acceptable.
2. Check your pharmacy’s formulary – Some independent pharmacies may stock an “unregistered” product, but these are not FDA‑approved and carry higher risk.
3. Insurance benefit manager (IBM) – Call the IBM to confirm whether the manufacturer’s PAP or other discount programs apply. |
---
Bottom line
- No generic esketamine nasal spray is currently approved in the U.S. or major markets.
- The brand‑name Spravato remains the sole legal option.
- Price is high—$650–$800 per vial—though insurance and PAPs can dramatically reduce your out‑of‑pocket cost.
If you’re considering treatment, your best next step is to talk to your prescriber or pharmacist about insurance coverage and any available assistance programs. They can also help you verify the most up‑to‑date pricing and explore whether any lower‑cost alternatives (e.g., intramuscular ketamine) might be clinically appropriate for your situation.